Featured

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

September 30, 2025

Lisata Therapeutics announced encouraging preliminary data from the Phase 1/2a CENDIFOX trial evaluating certepetide in combination with FOLFIRINOX fo...

September 25

OS Therapies to Present at BioFuture 2025 and Discuss OST-HER2 Clinical Development

OS Therapies Inc. announces its participation in the BioFuture 2025 conference, where it will present an overview of the company with a focus on the c...

September 19, 2025

Palvella Therapeutics Announces Publication on Rapamycin for Venous Malformations

Palvella Therapeutics announces a publication in Lymphatic Research and Biology highlighting advances in understanding venous malformation pathogenesi...

September 18, 2025

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

CeleCor Therapeutics announced positive topline results from its Phase 3 CeleBrate trial evaluating Disaggpro™ (zalunfiban) for heart attack treatment...

September 24, 2025

Lisata Therapeutics Announces Positive Preliminary Results from CENDIFOX Trial in Pancreatic Cancer

Lisata Therapeutics announced encouraging preliminary data from the Phase 1/2a CENDIFOX trial evaluating certepetide in combination with FOLFIRINOX fo...

September 30, 2025

ONWARD Medical Announces Positive Results for ARC-IM Therapy in Blood Pressure Regulation after Spinal Cord Injury

ONWARD Medical N.V. announced concurrent publications in Nature and Nature Medicine highlighting the benefits of its investigational ARC-IM System for...

September 18, 2025

Protagonist Announces Clinical Data Presentations for Icotrokinra and PN-881 at EADV 2025 Congress

Protagonist Therapeutics announced new clinical data for Icotrokinra in plaque psoriasis from Phase 3 ICONIC-ADVANCE and ICONIC-LEAD studies, being pr...

September 18, 2025

Skyhawk Therapeutics Announces Positive Interim Phase 1 Results for SKY-0515 in Huntington's Disease

Skyhawk Therapeutics announced positive interim results from its Phase 1 clinical trial of SKY-0515 for Huntington's disease (HD). The trial showed do...

September 18, 2025

August 25

Atossa Therapeutics Seeks Accelerated Approval for Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Atossa Therapeutics has requested a Type C meeting with the FDA to discuss a regulatory strategy for accelerating the development of low-dose (Z)-endo...

September 9, 2025

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

CASI Pharmaceuticals announced that the Safety Monitoring Committee (SMC) recommended dose escalation of CID-103, an anti-CD38 monoclonal antibody, to...

September 9, 2025

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...

September 9, 2025

Positive Phase 1/2 Data for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences announced positive data from a Phase 1/2 trial evaluating the combination of IDE397, a MAT2A inhibitor, and Trodelvy (sacituzumab g...

September 9, 2025

Positive Phase 1 Data for IDE849 (SHR-4849) in Small Cell Lung Cancer

IDEAYA Biosciences and Hengrui Pharma presented positive Phase 1 data for IDE849 (SHR-4849), a DLL3-targeting TOP1 antibody-drug conjugate (ADC), at t...

September 8, 2025

Oncolytics Biotech Highlights Pelareorep Efficacy in Metastatic Colorectal Cancer

Oncolytics Biotech announced positive clinical and translational data for pelareorep in metastatic colorectal cancer (mCRC). In the REO 022 trial, pe...

September 8, 2025

RYBREVANT® and LAZCLUZE® Combination Prevents Acquired Resistance in First-Line EGFR-Mutated NSCLC

Johnson & Johnson announced new analyses from the Phase 3 MARIPOSA study demonstrating that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCL...

September 8, 2025

iMDx Enrolls First Patient in GraftAssureDx Clinical Trial

Insight Molecular Diagnostics (iMDx) announced the enrollment of the first patient in its clinical trial for GraftAssureDx, a kitted organ transplant ...

September 8, 2025

Regeneron's Positive Phase 3 Allergy Trials Advance First-in-Class Antibody Blockers

Regeneron Pharmaceuticals announced positive results from two Phase 3 trials evaluating its first-in-class allergen-blocking antibodies for cat and bi...

September 8, 2025

Rapport Therapeutics to Announce Topline Phase 2a Results for RAP-219 in Focal Onset Seizures

Rapport Therapeutics will release topline data from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures on Sep...

September 8, 2025

SCYNEXIS Presents Data on Second-Generation Antifungal SCY-247 at TIMM-12

SCYNEXIS announced multiple presentations at the 12th Congress on Trends in Medical Mycology (TIMM-12) highlighting data on its second-generation anti...

September 5, 2025

Valitor Presents Preclinical Data on VLTR-559 for Wet AMD

Valitor announced positive preclinical data for VLTR-559, a long-acting anti-VEGF drug candidate for wet age-related macular degeneration (AMD). A no...

September 5, 2025

Gain Therapeutics Receives Approval for Phase 1b Dosing Extension of GT-02287 for Parkinson's Disease

Gain Therapeutics announced Australian approval to extend the Phase 1b clinical trial of its drug candidate, GT-02287, for Parkinson's disease by nine...

September 5, 2025

Clene Presents Preclinical Data Supporting CNM-Au8 for Parkinson's Disease

Clene Inc. announced positive preclinical data for CNM-Au8 in treating Parkinson's disease (PD). A novel neuronal model demonstrated CNM-Au8's abilit...

September 5, 2025

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...

September 4, 2025

Sanofi's Amlitelimab Shows Promise in Phase 3 Atopic Dermatitis Study

Sanofi announced positive topline results from the COAST 1 Phase 3 clinical trial of amlitelimab, a monoclonal antibody targeting OX40L, in adults and...

September 4, 2025

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

Aspire Biopharma announced positive final results from a clinical trial evaluating its investigational sublingual aspirin product for suspected acute ...

September 4, 2025

Personalis' NeXT Personal MRD Test Shows Superiority in Neoadjuvant Lung Cancer Trial

Personalis, Inc. announced positive data from AstraZeneca's phase 3 NeoADAURA trial, demonstrating that their NeXT Personal molecular residual disease...

September 4, 2025

Zymeworks Discontinues ZW171 Clinical Development

Zymeworks Inc. announced the discontinuation of clinical development for ZW171, a T cell engager targeting gynecological, thoracic, and digestive syst...

September 2, 2025

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

Compass Pathways announced the publication of positive Phase 2 results for their investigational drug COMP360, a synthetic psilocybin, in treating pos...

September 2, 2025

Ascletis to Present ASC30 Data at EASD Annual Meeting

Ascletis Pharma Inc. announced that it will present data from a 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R...

September 2, 2025

Merck's Enlicitide Decanoate Meets Primary Endpoints in Phase 3 Hypercholesterolemia Trial

Merck announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating enlicitide decanoate, an investigational oral PCSK9 inhibi...

September 2, 2025

Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients

Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyc...

September 2, 2025

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...

September 1, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

Alnylam Pharmaceuticals announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) for zilebesiran, an investigational RNAi therapeuti...

September 1, 2025

Roche and Alnylam Advance Zilebesiran into Phase III Cardiovascular Outcomes Trial for Uncontrolled Hypertension

Roche and Alnylam announced the initiation of a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an RNAi therapeutic, to reduce major a...

September 1, 2025

Merck's VERQUVO (vericiguat) Shows Mixed Results in Chronic Heart Failure Trials

Merck announced results from the Phase 3 VICTOR trial and a pooled analysis of VICTOR and VICTORIA trials evaluating VERQUVO (vericiguat) in chronic h...

September 1, 2025

Tourmaline Bio Presents Positive Phase 2 Data for Pacibekitug at ESC Congress 2025

Tourmaline Bio announced positive data from the ongoing Phase 2 TRANQUILITY trial of pacibekitug, a long-acting anti-IL-6 monoclonal antibody, present...

September 1, 2025

Telomir-1: A Novel Epigenetic Therapy Targeting DNA Methylation Pathways

Telomir Pharmaceuticals announced in vitro data supporting the potential of Telomir-1, a first-in-class epigenetic therapy, in treating cancer, aging,...

August 29, 2025

Zevra Therapeutics to Present Multiple Datasets on MIPLYFFA® (arimoclomol) at ICIEM

Zevra Therapeutics announced that four posters on MIPLYFFA® (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC), will be present...

August 29, 2025

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

Breath Diagnostics announced results from a peer-reviewed clinical study published in The Journal of Thoracic and Cardiovascular Surgery, demonstratin...

August 28, 2025

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

Airiver Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to conduct a pivotal clinical trial of its...

August 28, 2025

Actuate Therapeutics' Elraglusib Shows Promising Results in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive Phase 2 results for elraglusib (elra) in combination with gemcitabine and nab-paclitaxel (GnP) for metastatic ...

August 26, 2025

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS

Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, a biologic combination therapy for ...

August 25, 2025

Immuneering and Lilly Partner to Evaluate Atebimetinib and Olomorasib in Phase 2 NSCLC Trial

Immuneering Corporation announced a clinical supply agreement with Eli Lilly and Company for olomorasib, to be used in combination with Immuneering's ...

August 25, 2025

ITF Therapeutics Announces Positive Long-Term Givinostat Data for Duchenne Muscular Dystrophy

ITF Therapeutics announced the publication of positive long-term safety and efficacy data for givinostat in treating Duchenne muscular dystrophy (DMD)...

August 25, 2025

Napo Pharmaceuticals to Meet with FDA Regarding Crofelemer for Ultrarare Pediatric MVID

Napo Pharmaceuticals, a Jaguar Health family company, plans to meet with the FDA to discuss the clinical development program for crofelemer in treatin...

August 20, 2025

MIRA Pharmaceuticals Completes Phase 1 Trial of Oral Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals announced the successful completion of the single ascending dose (SAD) portion of its Phase 1 clinical trial for oral Ketamir-2, ...

August 20, 2025

Rocket Pharmaceuticals' Phase 2 Danon Disease Trial Resumes After FDA Lifts Clinical Hold

Rocket Pharmaceuticals announced that the FDA has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease. The hold was lif...

August 20, 2025

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day

IDEAYA Biosciences, Inc. announced the agenda for its 10-year anniversary R&D Day on September 8, 2025. The event will feature presentations on the c...

August 18, 2025

July 25

ZyVersa Therapeutics Highlights Data on Kidney Lipotoxicity in Diabetic Kidney Disease

ZyVersa Therapeutics announced data highlighting the critical need for therapies targeting kidney lipotoxicity in diabetic kidney disease (DKD). The ...

August 15, 2025

Largest-Ever Sickle Cell Disease Study Completed, Paving Way for New Treatments

Fifty1 AI Labs, in collaboration with The Gates Foundation and leading universities, has completed the largest-ever study of Sickle Cell Disease (SCD)...

August 15, 2025

Avant Technologies and Ainnova Tech Enhance Patient Recruitment for Diabetic Retinopathy AI Platform Clinical Trial

Avant Technologies and its joint venture partner, Ainnova Tech, announced an enhanced patient recruitment strategy for their Vision AI platform clinic...

August 13, 2025

Ocugen Announces Positive EMA Scientific Advice for OCU410ST Gene Therapy for Stargardt Disease

Ocugen, Inc. announced positive scientific advice from the European Medicines Agency (EMA) regarding the approval pathway for OCU410ST, a modifier gen...

August 13, 2025

Spectral Medical's Tigris Trial Shows Positive Results for PMX in Endotoxic Septic Shock

Spectral Medical and Vantive announced positive topline results from the Tigris Phase 3 trial evaluating Polymyxin B Hemoadsorption (PMX) for endotoxi...

August 13, 2025

Lilly's Oral GLP-1 Agonist, Orforglipron, Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial of orforglipron, an investigational oral GLP-1 receptor agoni...

Cassava Sciences Reports Positive Preclinical Study of Simufilam for TSC-Related Epilepsy

Cassava Sciences announced positive preclinical results for simufilam in a mouse model of tuberous sclerosis complex (TSC)-related epilepsy. The stud...

Praxis Precision Medicines Announces Positive Phase 2 Results for Vormatrigine in Focal Onset Seizures

Praxis Precision Medicines announced positive topline results from the Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. T...

Akebia Initiates Post-Marketing Study for Vafseo® (vadadustat) in CKD Anemia

Akebia Therapeutics announced the initiation of VOCAL, a post-marketing study evaluating the efficacy and safety of Vafseo® (vadadustat) administered ...

NeuroStar TMS Shows Efficacy in Treating Depression in Adolescents and Young Adults

Neuronetics, Inc. announced the publication of real-world data in JAACAP Open demonstrating the effectiveness of NeuroStar TMS therapy in adolescents ...

Research Advances from the 2025 Alzheimer's Association International Conference

The Alzheimer's Association International Conference® 2025 (AAIC®) presented new research on Alzheimer's disease and other dementias. Key findings in...

Anika Therapeutics Announces Topline Results from Hyalofast® Phase III Cartilage Repair Study

Anika Therapeutics announced topline results from its U.S. pivotal Phase III FastTRACK clinical trial of Hyalofast, a hyaluronic acid scaffold for car...

Neuvivo Secures FDA Alignment for NP001 ALS Treatment and Appoints Dr. John Curnutte to Board

Neuvivo, Inc., a late-stage biopharmaceutical company, announced it has reached an agreement with the FDA on the regulatory pathway for NP001, an immu...

VYNE Therapeutics' Phase 2b Repibresib Gel Trial for Vitiligo Misses Primary Endpoint

VYNE Therapeutics announced topline results from its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, involving 177 subje...

Tenaya Therapeutics Receives Positive Safety Reviews for TN-201 and TN-401 Gene Therapy Trials

Tenaya Therapeutics announced positive safety reviews from independent Data Safety and Monitoring Boards (DSMBs) for its two cardiovascular gene thera...

Atossa Therapeutics Receives Positive FDA Feedback for (Z)-Endoxifen in Metastatic Breast Cancer

Atossa Therapeutics announced positive feedback from the FDA regarding its proposed dose optimization trial of (Z)-endoxifen for ER+/HER2- metastatic ...

TauGen Files Patent Application for Novel TBI Drug Candidates

TauGen, LLC, in collaboration with CereMark Pharma, has filed a US patent application for a new class of drug candidates targeting traumatic brain inj...

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet AMD

EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 LUCIA trial evaluating DURAVYU™ for wet age-related macular degenerati...

Lilly's Jaypirca (pirtobrutinib) Meets Primary Endpoint in Phase 3 CLL/SLL Trial

Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent BTK...

Moderna Announces Data Presentation at ESMO Congress 2025

Moderna announced that three abstracts on its investigational mRNA therapeutics will be presented at the 2025 European Society for Medical Oncology (E...

Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced positive topline data from the open-label Phase 2 clinical trial (ATH434-202) of ATH434 in patients with multiple syst...

Fulcrum Therapeutics Announces Positive Phase 1b Results for Pociredir in Sickle Cell Disease

Fulcrum Therapeutics reported positive results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD). Th...

Serina Therapeutics Advances POZ-VMAT2i for Tardive Dyskinesia

Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i), a novel, once-weekly injectable VMAT2 inhibitor, for treating tardive dyskinesi...

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in Uveal Melanoma

IDEAYA Biosciences announced that data from a Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 20...

GH Research Announces Global Pivotal Program Plans for GH001 and GH002

GH Research PLC provided updates on its clinical-stage biopharmaceutical programs. The company announced a response from the FDA regarding its Invest...

Xenetic Biosciences Expands Collaboration to Advance DNase-Based Oncology Platform

Xenetic Biosciences announced the expansion of its research collaboration with The Scripps Research Institute (TSRI) to further develop its DNase I-ba...

Diakonos Oncology Initiates Phase 2 Trial of DOC1021 for Glioblastoma

Diakonos Oncology announced the first patient has been dosed in a Phase 2 clinical trial evaluating DOC1021, a novel patient-derived double-loaded den...

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day

IDEAYA Biosciences will host an R&D Day on September 8, 2025, to present clinical data updates across its pipeline and outline its future growth strat...

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results for ILUVIEN in Diabetic Macular Edema

ANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic ma...

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax announced positive topline results from its Phase 3 ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer,...

Oruka Therapeutics Announces IND Clearance for Phase 2a Trial of ORKA-001 in Psoriasis

Oruka Therapeutics announced that the FDA cleared its Investigational New Drug (IND) application for a Phase 2a trial (EVERLAST-A) of ORKA-001, a long...

UroGen's ZUSDURI Shows Long-Term Efficacy in Non-Muscle Invasive Bladder Cancer

UroGen Pharma announced the publication of five-year long-term extension study results from the Phase 2b OPTIMA II trial. The study evaluated ZUSDURI...

Tiziana Life Sciences Announces Promising Immunologic Findings of Nasal Foralumab in Alzheimer's Disease

Tiziana Life Sciences announced compelling immunologic findings from a moderate Alzheimer's Disease patient treated with intranasal foralumab. Transc...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...

Renovaro's Genetically Engineered Dendritic Cell Therapy Shows Potent Anti-Tumor Efficacy in Preclinical Study

Renovaro Biosciences announced the publication of a peer-reviewed study in *Vaccines* demonstrating the significant anti-tumor efficacy of its next-ge...

Ocugen Initiates Phase 2/3 Trial for Stargardt Disease Gene Therapy

Ocugen, Inc. announced the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a novel modifier gene therapy for Starg...

Keros Therapeutics Initiates Phase 3 Trial of Elritercept for MDS

Keros Therapeutics announced the first patient dosing in the Phase 3 RENEW clinical trial of elritercept for adults with transfusion-dependent anemia ...

June 25

OKYO Pharma's Urcosimod Shows Promising Phase 2 Results for Neuropathic Corneal Pain

OKYO Pharma announced positive top-line data from its Phase 2 trial of urcosimod for treating neuropathic corneal pain (NCP). The 18-patient trial sh...

Oragenics Announces U.S. Manufacturing Agreement for ONP-002 Concussion Treatment

Oragenics, Inc. has partnered with Sterling Pharma Solutions for the Good Manufacturing Practice (GMP) production of ONP-002, its lead drug candidate ...

NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291

NervGen Pharma Corp. announced a leadership transition with Dr. Adam Rogers appointed as Interim CEO, following the positive topline results from the ...

Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program

Voyager Therapeutics announced a new wholly-owned Alzheimer's disease (AD) program targeting apolipoprotein E (APOE), a major genetic risk factor for ...

Avant Technologies and Ainnova Complete Pivotal FDA Meeting for Vision AI Diabetic Retinopathy Platform

Avant Technologies and its JV partner, Ainnova, announced the completion of a pre-submission meeting with the U.S. FDA regarding Ainnova's Vision AI p...

Neurocrine Biosciences Presents CAHtalog Registry Analysis at ENDO 2025

Neurocrine Biosciences announced results from a new analysis of the CAHtalog registry, showing that most patients with classic congenital adrenal hype...

Palatin Announces Positive Preclinical Data for Oral MC4R Agonist PL7737 in Obesity

Palatin Technologies announced positive preclinical results for PL7737, an oral MC4R agonist, demonstrating significant weight loss in obese rodent mo...

Danish Study Finds No Link Between Aluminum in Vaccines and 50 Health Conditions

A large-scale Danish register-based study involving over 1 million children found no association between aluminum in childhood vaccines and 50 health ...

Monteris Medical Announces Positive JAMA Neurology Publication on NeuroBlate System for Epilepsy

Monteris Medical announced the publication of a landmark study in JAMA Neurology demonstrating the safety, durability, and efficacy of laser interstit...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...

Takeda's Oveporexton Shows Positive Phase 3 Results for Narcolepsy Type 1

Takeda announced positive topline results from two pivotal Phase 3 studies (FirstLight and RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1...

MiNK Therapeutics Announces Complete Remission in Metastatic Testicular Cancer Using iNKT Cell Therapy

MiNK Therapeutics announced the publication of a case report in *Oncogene* showing complete and durable remission in a patient with metastatic, treatm...

Cerevance to Present Phase 1 Data on CVN293, a KCNK13 Inhibitor, at AAIC 2025

Cerevance announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025. Key presentations include Phase 1 dat...

Silexion Therapeutics Announces Positive Preclinical Results for SIL204 in Lung Cancer

Silexion Therapeutics announced positive preclinical data showing SIL204's significant efficacy in human lung cancer cell lines. SIL204, an RNA inter...

KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect

KALA BIO announced the completion of patient enrollment in the CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secreto...

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood Test

Cizzle Bio, a biotechnology company, submitted a grant application to the NIH for a two-year study validating its CIZ1B biomarker for early-stage lung...

MediView Launches Multicenter Study for XR90 Surgical Navigation System in Soft Tissue Biopsy

MediView has initiated a multicenter clinical study to evaluate the XR90 Holographic Surgical Navigation system's effectiveness in percutaneous soft t...

Plus Therapeutics Announces Initial Patient Treatment in REYOBIQ™ Leptomeningeal Metastases Dose Optimization Trial

Plus Therapeutics announced the treatment of the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re186 obisbemeda) in l...

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced updated survival data from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC...

Caris Assure® Blood-Based Assay Shows Promise for Multi-Cancer Early Detection and Monitoring

Caris Life Sciences announced a study published in Scientific Reports demonstrating the accuracy and clinical utility of its Caris Assure® blood-based...

MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia

MapLight Therapeutics has begun a Phase 2 clinical trial (ZEPHYR) to assess the efficacy, safety, and tolerability of ML-007C-MA, a novel M1/M4 muscar...

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025

Soleno Therapeutics announced that two presentations featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the treatment of hyp...

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...

Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...

Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy KLTO-202

Klotho Neurosciences announced it is progressing with manufacturing and process development for KLTO-202, a gene therapy targeting amyotrophic lateral...

MeCo Score: A Novel Biomarker for Predicting Response to Antifibrotic Therapy in Breast Cancer

A multinational study published in the journal *Cancers* reveals that the MeCo Score, a novel biomarker, quantifies mechanical conditioning in breast ...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna announced positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010. The study demonstrated a 26.6% higher relative va...

Edgewise Therapeutics Announces Positive Sevasemten Results for Becker and Duchenne Muscular Dystrophy

Edgewise Therapeutics reported positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. In Becker MD, open-label da...

DBV Technologies Begins Phase 3 Safety Study for Viaskin Peanut Patch in Peanut-Allergic Toddlers

DBV Technologies announced the first subject has been screened in its COMFORT Toddlers study, a Phase 3 supplemental safety study evaluating the Viask...

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a novel formulation of methotrexate...

GeneDx's SeqFirst Study Shows Rapid Genomic Testing Significantly Improves Pediatric Diagnosis

GeneDx announced data from the SeqFirst study, conducted in partnership with Seattle Children's, demonstrating the effectiveness of rapid exome sequen...

Oncotelic Therapeutics Announces Publication Showing TGFB2 Methylation as Positive Prognostic Marker in Pancreatic Cancer

Oncotelic Therapeutics announced the publication of a study in the *International Journal of Molecular Sciences* showing that TGFB2 gene methylation i...

ONCare Alliance and Exigent Research Launch Outpatient Bispecifics Cancer Treatment Program

ONCare Alliance and Exigent Research have launched a groundbreaking outpatient bispecific antibody program for cancer treatment. This program, develo...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a bioresorbable tendon protector, for...

Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD

Vial, a clinical-stage biotechnology company, announced the first-in-human dosing of its novel, subcutaneous, half-life extended monoclonal antibody t...

Enterra Medical Initiates NAVIGATE Study for Gastric Electrical Stimulation (GES) in Chronic Nausea

Enterra Medical has launched the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) for treating chronic ...

Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in MS

Immunic, Inc. announced positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relaps...

Qlaris Bio to Present New Data on QLS-111 for Glaucoma at World Glaucoma Congress

Qlaris Bio announced that new clinical and preclinical data on its lead investigational compound, QLS-111, will be presented at the 2025 World Glaucom...

Novo Nordisk Advances Amycretin, an Obesity Medication, to Phase 3 Clinical Development

Novo Nordisk announced positive results from two early-phase clinical trials of amycretin, a novel investigational obesity treatment, published in The...

Compass Pathways' COMP360 Psilocybin Shows Positive Phase 3 Results for Treatment-Resistant Depression

Compass Pathways announced positive top-line results from its Phase 3 COMP005 trial evaluating COMP360, a synthetic psilocybin formulation, for treatm...

Soleno Therapeutics Announces Presentations on Diazoxide Choline for Prader-Willi Syndrome at International Conference

Soleno Therapeutics announced multiple presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference. The presentations wi...

Poxel SA Highlights Imeglimin's Potential at ADA 2025

Poxel SA announced that five presentations on the therapeutic potential of Imeglimin (TWYMEEG®), a first-in-class treatment for type 2 diabetes, will ...

UCB Presents Thymidine Kinase 2 Deficiency (TK2d) Research at UMDF 2025 Conference

UCB presented new research on thymidine kinase 2 deficiency (TK2d) at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference. The present...

Indivior Presents Data on SUBLOCADE for Opioid Use Disorder in High Fentanyl Users

Indivior presented new data at the College on Problems of Drug Dependence (CPDD) meeting, showing that a higher dose (300mg) of SUBLOCADE (buprenorphi...

May 25

KalVista Pharmaceuticals Presents Positive Data on Sebetralstat for On-Demand HAE Treatment

KalVista Pharmaceuticals announced positive data from the KONFIDENT-S trial at the EAACI Congress 2025, showcasing sebetralstat's efficacy as an oral,...

Novo Nordisk Advances Amycretin for Weight Management to Phase 3

Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...

ITM to Present COMPETE Trial Data at SNMMI 2025 Annual Meeting

ITM Isotope Technologies Munich SE announced that it will present further analysis from its completed Phase 3 COMPETE trial at the SNMMI 2025 annual m...

Promising Antileukemic Activity of Bleximenib in Combination Therapy for Acute Myeloid Leukemia

Johnson & Johnson announced positive Phase 1b data for bleximenib, a menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid...

Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...

BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years

UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...

Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial

Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...

MolecuLight Imaging Improves Deep Sternal Wound Infection Outcomes and Reduces Costs in Taiwan Study

A clinical study published in the Journal of Wound Care demonstrates that MolecuLight's i:X® device significantly improves outcomes for deep sternal w...

Kazia Therapeutics Announces Preclinical Data on Paxalisib for Triple-Negative Breast Cancer

Kazia Therapeutics announced the publication of preclinical research in Molecular Cancer Therapeutics demonstrating paxalisib's potential to overcome ...

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid Tumors

BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Travere Therapeutics announced it will present new data on FILSPARI (sparsentan) at the International Podocyte Conference. Data from the Phase 2 SPAR...

Harmony Biosciences Presents Preclinical Data for BP1.15205, a Potential Best-in-Class OX2R Agonist for Narcolepsy

Harmony Biosciences announced positive preclinical data for BP1.15205, a novel orexin 2 receptor (OX2R) agonist, demonstrating significant wake-promot...

Masimo SedLine® Improves Pediatric Anesthesia Outcomes

A randomized clinical trial published in JAMA Pediatrics demonstrates that EEG-guided anesthesia using Masimo SedLine® Brain Function Monitoring signi...

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up Results

Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...

Novo Nordisk to Present New Data on Semaglutide, CagriSema, and Amycretin at ADA 2025

Novo Nordisk announced it will present new data at the American Diabetes Association (ADA) 85th Scientific Sessions in June 2025. This includes Phase...

Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial

Vergent Bioscience announced positive Phase 2B VISUALIZE trial results for abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent. The tr...

Hologic Presents New Data on Breast Cancer Index® Test at ASCO 2025

Hologic announced new data on the Breast Cancer Index® (BCI®) test, to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Me...

Servier to Present Updates on IDH-Mutated Cancer Research at ASCO 2025

Servier announced it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Presenta...

Tiziana Life Sciences Highlights Intranasal Foralumab for Moderate Alzheimer's Disease

Tiziana Life Sciences announced positive advancements in moderate Alzheimer's disease treatment using intranasal foralumab, a fully human anti-CD3 mon...

Positive Updated Results for Avutometinib Plus Defactinib in Frontline Metastatic Pancreatic Cancer

Verastem Oncology announced positive updated results from the RAMP 205 Phase 1/2 trial evaluating the combination of avutometinib and defactinib with ...

CytoSorbents Therapy Reduces Bleeding in Urgent CABG Patients on Ticagrelor

CytoSorbents Corporation announced results from a real-world data analysis presented at EuroPCR 2025, showing that its CytoSorbents therapy significan...

EMD Serono Presents Oncology Data at ASCO 2025

EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...

Daiichi Sankyo Presents Practice-Changing ENHERTU Data at ASCO 2025

Daiichi Sankyo announced positive late-breaking data from two phase 3 trials, DESTINY-Breast09 and DESTINY-Gastric04, highlighting ENHERTU (trastuzuma...

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy

ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...

Alligator Bioscience Presents Positive Biomarker Data for Mitazalimab in Pancreatic Cancer at ASCO 2025

Alligator Bioscience announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 ASCO Annual Meeting. OPTIMIZE-1 is a ...

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment Outcomes

MiraDx announced two studies to be presented at ASCO 2025, showcasing their mirSNP platform's ability to predict treatment-related toxicity and respon...

HUTCHMED to Present Clinical Data at 2025 ASCO Annual Meeting

HUTCHMED announced that new data from several clinical studies of its compounds, including savolitinib, ranosidenib, fruquintinib, and surufatinib, wi...

SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025

SystImmune, Inc. announced that data from clinical trials evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjuga...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

Biodesix to Present VeriStrat® Test Data at ASCO 2025

Biodesix announced new data from the INSIGHT study (NCT03289780) on the VeriStrat® Host Immune Classifier (HIC) test, to be presented at the 2025 ASCO...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...

Linvoseltamab Combination Therapy Shows Promising Results in Multiple Myeloma

Regeneron Pharmaceuticals announced positive initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with carfilzom...

Legend Biotech Presents New Data on CARVYKTI® and Pipeline Candidates at ASCO, EHA, and ASGCT

Legend Biotech announced new data on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma, to be presented at ASCO and EHA. Lo...

Genmab to Present Late-Stage Oncology Data at ASCO 2025

Genmab announced it will present new data at the 2025 ASCO Annual Meeting, focusing on its late-stage oncology portfolio. Key highlights include the ...

Bicycle Therapeutics Announces Positive Clinical Trial Results for Zelenectide Pevedotin at ASCO 2025

Bicycle Therapeutics announced the presentation of two abstracts at the 2025 ASCO Annual Meeting, showcasing preliminary results from their Phase 1/2 ...

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025

Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...

Columvi Extends Overall Survival in Relapsed/Refractory DLBCL Patients: Two-Year Follow-up Data

Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapse...

Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting

Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...

Exact Sciences Highlights Cancer Detection Innovations at ASCO 2025

Exact Sciences announced the presentation of ten abstracts at the 2025 ASCO Annual Meeting, showcasing new data on its Oncodetect MRD test, multi-canc...

Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis

Gyre Therapeutics announced positive Phase 3 results for Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B (CHB) in Ch...

Guardant Health to Present Liquid Biopsy Data at ASCO 2025

Guardant Health announced that it and its collaborators will present data from over 19 studies at the 2025 ASCO Annual Meeting. These studies highlig...

Kelun-Biotech Presents Positive Clinical Trial Data at ASCO 2025

Kelun-Biotech announced the publication of six abstracts from its clinical studies at the 2025 ASCO Annual Meeting. The abstracts highlight data on t...

ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025

ImPact Biotech announced that it will present interim data from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with low-grade upper tract...

Lilly Announces ASCO 2025 Presentations on Oncology Pipeline

Eli Lilly and Company announced that data from several investigational oncology therapies will be presented at the 2025 American Society of Clinical O...

Astria Therapeutics to Present Navenibart Data at C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics announced that it will present safety and efficacy data from Phase 1a and 1b/2 clinical trials of navenibart, a monoclonal antibod...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim announced that it will present new clinical data from two early-stage trials investigating SIRPα inhibitors at the 2025 ASCO Annu...

Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck Cancer

Merus N.V. announced positive interim data from a Phase 2 trial of petosemtamab in combination with pembrolizumab for first-line treatment of PD-L1+ r...

XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial (NCT02677896) demonstrates that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) s...

Rakuten Medical Announces Phase 3 Trial Progress for ASP-1929 Photoimmunotherapy at ASCO 2025

Rakuten Medical announced that it will present a Trial in Progress poster at the 2025 ASCO Annual Meeting, showcasing its global Phase 3 clinical tria...

Positive Phase II Results for CARsgen's Satri-cel in Advanced Gastric Cancer

CARsgen Therapeutics announced positive results from a Phase II clinical trial (CT041-ST-01, NCT04581473) of satricabtagene autoleucel (satri-cel), a ...

Vistagen to Present Research on Itruvone and Fasedienol at ASCP Conference

Vistagen, a clinical-stage biopharmaceutical company, announced it will present at the 2025 American Society of Clinical Psychopharmacology (ASCP) Con...

Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC

Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...

Pfizer to Present Phase 1 Data on MesoC2 ADC at ASCO 2025

Nona Biosciences announced that its collaborator, Pfizer, will present the Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-c...

Bristol Myers Squibb to Present Oncology Data at ASCO 2025

Bristol Myers Squibb announced the presentation of data from over 80 studies at the 2025 ASCO Annual Meeting. The data covers more than 20 cancer typ...

Updated Elacestrant Data Highlights Combinability in Metastatic Breast Cancer

Menarini Group presented updated data from the Phase 1b/2 ELEVATE study at ASCO 2025, showcasing the efficacy and safety of elacestrant (ORSERDU®) in ...

Taiho Oncology Presents Positive Data at ASCO 2025 Annual Meeting

Taiho Oncology announced new data to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include data on...

Merus' Bispecific Antibody Shows Promising Results in Head and Neck Cancer

Merus announced positive Phase II data for its bispecific antibody petosemtamab in combination with Keytruda (pembrolizumab) for first-line treatment ...

RWJBarnabas Health and Rutgers Cancer Institute to Present Cancer Research at ASCO 2025

RWJBarnabas Health and Rutgers Cancer Institute will present 45 abstracts and presentations at the 2025 ASCO Annual Meeting. Research highlights incl...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...

Exelixis Presents Encouraging Zanzalintinib Combination Therapy Results for Advanced Kidney Cancer at ASCO 2025

Exelixis announced positive results from the Phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors fo...

Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis

Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...

Improved Cardiac Surgery Outcomes with Active Chest Tube Clearance

ClearFlow, Inc. announced positive clinical trial results showing that its PleuraFlow Active Clearance Technology (ACT) System significantly improves ...

Avalyn Pharma Presents Positive Clinical Data for Inhaled Pulmonary Fibrosis Treatments at ATS 2025

Avalyn Pharma showcased positive clinical data for its lead programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), at the American Thorac...

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal Degeneration

Drs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface Implant

ONWARD Medical announced the successful implantation of its investigational ARC-BCI® Therapy in two additional individuals with spinal cord injury, br...

Zymeworks Presents Preclinical Data for ZW1528, a Novel Bispecific Antibody for Respiratory Inflammation

Zymeworks announced the presentation of preclinical data for ZW1528, a novel bispecific molecule targeting IL-4Rα and IL-33, at the American Thoracic ...

Be Biopharma Announces Preclinical Data for BE-102 in Hypophosphatasia

Be Biopharma presented preclinical data for BE-102, a B cell medicine, showing continuous secretion of active alkaline phosphatase (ALP) for up to six...

IMVARIA Presents Multi-Site Clinical Data on AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025

IMVARIA Inc. announced the presentation of multi-site clinical experience results with its FDA-authorized AI diagnostic service, Fibresolve, at the AT...

Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension

Tectonic Therapeutic announced positive complete results from Part A of its Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hyperte...

Innate Pharma's Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma announced that four abstracts featuring its clinical-stage drugs will be presented at the American Society of Clinical Oncology (ASCO) 2...

LIfT BioSciences Presents Preclinical Data on Immunomodulatory Alpha Neutrophils (IMANs) for Solid Tumors

LIfT BioSciences announced the presentation of preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) at the ISCT 2025 Annu...

Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB announced promising preclinical results for CAN10, an antibody targeting IL1RAP, in vascular inflammation models. The study, published i...

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH

CureGene Pharmaceuticals announced preclinical data for its investigational drug, CG-0416, a liver-targeted thyroid hormone receptor beta (THR-β) prod...

Home/KnloSights/clinical trial updates